NCT06680089 CD70-targeted immunoPET Imaging of Kidney Cancer
| NCT ID | NCT06680089 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | RenJi Hospital |
| Condition | Urologic Neoplasms |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2024-11-27 |
| Primary Completion | 2026-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 300 participants in total. It began in 2024-11-27 with a primary completion date of 2026-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to establish and optimize the \[18F\]RCCB6 PET/CT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agent in renal cancer (especially clear cell renal cell carcinoma) wil be evaluated.
Eligibility Criteria
Inclusion Criteria: 1. Aged 18-80 year-old and of either sex； 2. Histologically confirmed diagnosis of kidney cancer (especially clear cell renal cell carcinoma and papillary renal cell carcinoma) or suspected kidney cancer by diagnostic imaging; 3. Capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the informed consent form (ICF) and this protocol. Exclusion Criteria: 1. Pregnancy； 2. Severe hepatic and renal insufficiency; 3. History of serious surgery in the last month; 4. Allergic to antibody or single-domain antibody radiopharmaceuticals.
Contact & Investigator
Wei Zhai, Ph.D. & M.D.
STUDY CHAIR
Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
Frequently Asked Questions
Who can join the NCT06680089 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Urologic Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06680089 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06680089 currently recruiting?
Yes, NCT06680089 is actively recruiting participants. Contact the research team at wwei@shsmu.edu.cn for enrollment information.
Where is the NCT06680089 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06680089 clinical trial?
NCT06680089 is sponsored by RenJi Hospital. The principal investigator is Wei Zhai, Ph.D. & M.D. at Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University. The trial plans to enroll 300 participants.